---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062019"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:18:01.259522+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nkarta reports Q3 net loss $25.6M; cash $278.4M; extends runway into 2026

## Summary
- Net loss of $25.6M ($0.52 per share) for Q3 2023; R&D expenses $22.2M, G&A $7.1M.
- Cash and investments $278.4M as of Sep 30, 2023; cost containment extends cash runway into 2026.
- FDA cleared IND for NKX019 in lupus nephritis; first patient dosing expected H1 2024.
- Workforce reduced ~10%; operations centralization and manufacturing optimization underway.
- Clinical data updates in 2024: NKX101 AML, NKX019 NHL compressed dosing, LN.

## SEC filing metadata
- accession: 0000950170-23-062019
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017023062019/0000950170-23-062019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017023062019/nktx-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062019
- JSON: https://secwatch.observer/filing/0000950170-23-062019.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062019.txt

## Key facts
- Earnings Releases
  Nkarta, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, Nkarta, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787400/000095017023062019/0000950170-23-062019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.